NSEDCP
ESPR

NJ State Employees Deferred Compensation Plan’s Esperion Therapeutics ESPR Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-195,125
Closed -$517K – 132
2025
Q3 		$517K Hold
195,125
– – 0.06% 282
2025
Q2 		$192K Hold
195,125
– – 0.02% 402
2025
Q1 		$281K Hold
195,125
– – 0.04% 365
2024
Q4 		$429K Hold
195,125
– – 0.05% 318
2024
Q3 		$322K Hold
195,125
– – 0.04% 360
2024
Q2 		$433K Hold
195,125
– – 0.05% 309
2024
Q1 		$523K Hold
195,125
– – 0.07% 277
2023
Q4 		$583K Hold
195,125
– – 0.08% 255
2023
Q3 		$191K Hold
195,125
– – 0.03% 432
2023
Q2 		$271K Hold
195,125
– – 0.04% 390
2023
Q1 		$310K Buy
195,125
+185,000
+1,827% +$955K 0.05% 369
2022
Q4 		$63.1K Hold
10,125
– – 0.01% 469
2022
Q3 		$68K Hold
10,125
– – 0.01% 462
2022
Q2 		$65K Hold
10,125
– – 0.01% 463
2022
Q1 		$47K Hold
10,125
– – 0.01% 493
2021
Q4 		$51K Hold
10,125
– – 0.01% 496
2021
Q3 		$122K Hold
10,125
– – 0.02% 490
2021
Q2 		$214K Hold
10,125
– – 0.03% 476
2021
Q1 		$284K Hold
10,125
– – 0.04% 414
2020
Q4 		$263K Hold
10,125
– – 0.04% 406
2020
Q3 		$376K Hold
10,125
– – 0.07% 271
2020
Q2 		$519K Hold
10,125
– – 0.1% 209
2020
Q1 		$320K Hold
10,125
– – 0.07% 268
2019
Q4 		$603K Hold
10,125
– – 0.1% 217
2019
Q3 		$372K Hold
10,125
– – 0.07% 327
2019
Q2 		$471K Hold
10,125
– – 0.08% 285
2019
Q1 		$406K Hold
10,125
– – 0.07% 336
2018
Q4 		$466K Sell
10,125
-1,000
-9% -$48.2K 0.1% 240
2018
Q3 		$494K Sell
11,125
-4,000
-26% -$184K 0.08% 320
2018
Q2 		$592K Buy
15,125
+4,000
+36% +$202K 0.11% 258
2018
Q1 		$805K Sell
11,125
-2,000
-15% -$147K 0.14% 196
2017
Q4 		$864K Hold
13,125
– – 0.15% 189
2017
Q3 		$658K Buy
+13,125
New +$633K 0.12% 262

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's ESPR Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 195,125 shares — an estimated $517K sold.

NJ State Employees Deferred Compensation Plan first reported a position in ESPR in Q3 2017 and held it in 33 quarters. The position peaked at $864K in Q4 2017. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • NJ State Employees Deferred Compensation Plan reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • NJ State Employees Deferred Compensation Plan sold 195,125 Esperion Therapeutics shares in Q4 2025, an estimated $517K.
  • NJ State Employees Deferred Compensation Plan first reported a position in Esperion Therapeutics in Q3 2017 and held it in 33 quarters.
  • NJ State Employees Deferred Compensation Plan's Esperion Therapeutics position peaked at $864K in Q4 2017.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.